Advertisement

Topics

Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500

06:34 EDT 13 Oct 2018 | BioPortfolio Reports

Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 Pipeline Review, H2 2018


Summary


Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 Stromal cellderived factor 1 SDF1 or CXC motif chemokine 12 CXCL12 is a chemokine protein encoded by the CXCL12 gene. It activates the CXC chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. It binds to atypical chemokine receptor ACKR3, which activates the betaarrestin pathway and acts as a scavenger receptor for SDF1. It acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase. It stimulates migration of monocytes and Tlymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM1.


Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 4 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.


Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genetic Disorders, Hematological Disorders, Immunology and Toxicology which include indications Pancreatic Ductal Adenocarcinoma, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, BCell Chronic Lymphocytic Leukemia, Chemotherapy Effects, Chronic Heart Failure, Critical Limb Ischemia, Fecal Incontinence, Glioblastoma Multiforme GBM, Glioma, Metastatic Cancer, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Neutropenia, Pancreatic Islet Transplant Rejection, Peripheral Arterial Disease PAD/ Peripheral Vascular Disease PVD, Primary Immune Deficiency PID, Refractory Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia and Traumatic Brain Injury.


The latest report Stromal Cell Derived Factor 1 Pipeline Review, H2 2018, outlays comprehensive information on the Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12

The report reviews Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 targeted therapeutics and enlists all their major and minor projects

The report assesses Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Stromal Cell Derived Factor 1 CXC Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12 Pipeline Review, H2 2018 [Report Updated: 14082018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...